EUVIMEDEUVIMED entdecken
Crossref

Mycophenolate mofetil associates with COVID-19 hospitalization in patients with systemic lupus erythematosus: a nationwide population-based study from China

Sitian Zang, Ruihe Liu, Liang Luo, Yi Li, Yan Wang, Jing Li, Bo Huang, Ranran Yao, Yipeng Han, Chun Li, Zhanguo Li

Clinical Rheumatology · 2026-06 · 45 (6) · 3257-3267

DOI: 10.1007/s10067-026-08032-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 06.04.2026. Verfasst von Sitian Zang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Mycophenolic Acid, Hospitalization, COVID-19. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China International Medical Foundation, Peking University Clinical Scientist Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/OBJECTIVES: To evaluate the impact of BA.5.2/BF.7 infections on the severity of systemic lupus erythematosus (SLE) and to identify associated risk factors. METHODS: A cross-sectional study was conducted from January 6 to February 19, 2023. The study population included SLE patients and healthy controls infected with the BA.5.2/BF.7 variants. Odds ratios (ORs), risk differences (RDs), and their corresponding 95% confidence intervals (CIs) were calculated to assess the effects of infection on SLE severity and to explore related risk factors. RESULTS: A total of 1,013 SLE patients and 2,125 healthy controls who were infected with BA.5.3/BF.7 were enrolled in the study. After adjusting for age, sex, comorbidities, and vaccination status, SLE was significantly associated with an increased risk of COVID-19 hospitalization (adjusted OR [aOR] 6.13, 95% confidence interval [CI] 3.06 to 12.27, p < 0.001). Among SLE patients, COVID-19 infection was associated with an increased risk of rash (risk difference [RD] 4.0%, 95% CI 1.5 to 6.6; p = 0.002), alopecia (RD 4.2%, 95% CI 0.9 to 7.6; p = 0.016), and mucosal ulcers (RD 3.3%, 95% CI 0.8 to 5.7; p = 0.012). Among SLE patients, the use of mycophenolate mofetil (MMF) was significantly associated with an increased risk of COVID-19 hospitalization (aOR 1.99, 95% CI 1.06 to 3.74; p = 0.033). CONCLUSIONS: These findings highlight the importance of a nuanced approach in managing SLE patients with COVID-19. Key Points • The COVID-19 pandemic spread widely across China. However, the impact of systemic lupus erythematosus (SLE) medications on COVID-19-related hospitalization remains unclear. • Our study found that treatment with mycophenolate mofetil in SLE patients was associated with a higher risk of hospitalization for COVID-19. • These findings should alert policymakers and clinicians to the need for a more nuanced and cautious approach when managing SLE patients infected with the Omicron BA.5.2 or BF.7 subvariants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicMycophenolic AcidHospitalizationCOVID-19Immunosuppressive AgentsHumansFemaleAdultChinaMaleCross-Sectional StudiesMiddle AgedRisk FactorsSARS-CoV-2Severity of Illness IndexPandemics

Stichwörter der Autor:innen

COVID-19 hospitalizationMycophenolate mofetilNationwide population-based studySystemic lupus erythematosus

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.
  • Department of Chinese Medicine, The People's Hospital of Yubei District of Chongqing City, 23 North Central Park Road, Chongqing, China.
  • School of Statistics and Mathematics, Nanjing Audit University, 86 Yushan West Road, Jiangpu Street, Nanjing, China.
  • Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China. 13811190098@163.com.
  • Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China. li99@bjmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • China International Medical Foundation
  • Peking University Clinical Scientist Training Program
  • Postdoctoral Fellowship Program of CPSF

Zitieren

APA

Zang, S., Liu, R., Luo, L., Li, Y., Wang, Y., Li, J., Huang, B., Yao, R., Han, Y., Li, C., & Li, Z. (2026). Mycophenolate mofetil associates with COVID-19 hospitalization in patients with systemic lupus erythematosus: a nationwide population-based study from China. Clinical Rheumatology, 45(6), 3257-3267. https://doi.org/10.1007/s10067-026-08032-y

Vancouver

Zang S, Liu R, Luo L, Li Y, Wang Y, Li J, et al. Mycophenolate mofetil associates with COVID-19 hospitalization in patients with systemic lupus erythematosus: a nationwide population-based study from China. Clinical Rheumatology. 2026;45(6):3257-3267. doi:10.1007/s10067-026-08032-y

BibTeX
@article{Zang2026,
  author = {Zang, Sitian and Liu, Ruihe and Luo, Liang and Li, Yi and Wang, Yan and Li, Jing and Huang, Bo and Yao, Ranran and Han, Yipeng and Li, Chun and Li, Zhanguo},
  title = {Mycophenolate mofetil associates with COVID-19 hospitalization in patients with systemic lupus erythematosus: a nationwide population-based study from China},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {6},
  pages = {3257--3267},
  doi = {10.1007/s10067-026-08032-y}
}
Kostenlos starten →